CK0802 for COVID-19: real-time analysis

Download Image

Post

c19early.org

CK0802 for COVID-19

1 study with 30 patients

Serious outcome risk

CK0802

Control

No significant improvements are seen in meta-analysis to date.

COVID-19 CK0802 studies · October 2026

Outcome (studies)

Improvement

Relative risk · 95% CI

All studies (1)−8%

Mortality (1)−8%

RCTs (1)−8%

Late (1)−8%

00.511.5+

← CK0802
reduces riskIncreased
risk →

.hmva--anim-stagger .hmva__row{opacity:1}.hmva--anim .hmva__shade{opacity:var(--shade-opacity)}.hmva--anim-stagger .est .ci{transform:translateY(-50%)}.hmva--anim-stagger .est .pt{transform:translate(-50%,-50%)}.hmva--anim-stagger .hmva__bar{transform:none}.hmva--anim-settle .est .pt{left:calc(min(var(--pt), 1.5) / var(--max) * 100%)}.hmva--anim-settle .est .ci{left:calc(var(--lo) / var(--max) * 100%);width:calc((var(--hi) - var(--lo)) / var(--max) * 100%)}.hmva--anim-settle .hmva__bar--drug{width:calc(min(1, var(--rr)) * 100%)}.hmva--anim-settle .hmva__bar--control{width:calc(min(1, 1 / var(--rr)) * 100%)}


Jun 30 2023	Gladstone et al., Blood Advances, doi:10.1182/bloodadvances.2022009619	Randomized, double-blinded, placebo-controlled trial of allogeneic cord blood T-regulatory cells for treatment of COVID-19 ARDS
Jun 30 2023	8% higher mortality (p=0.91) and 27% higher combined mortality/intubation (p=0.42). RCT 45 critically ill COVID-19 ARDS patients showing no significant difference with allogeneic cord blood T-regulatory cells (Tregs). Patients were randomized to receive placebo, 100 million Tregs, or 300 million Tregs with three infusion..